Biologic Properties of Endothelial Progenitor Cells and Their Potential for Cell Therapy

Pampee P. Young*, Douglas E. Vaughan, Antonis K. Hatzopoulos

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

120 Scopus citations


Recent studies indicate that portions of ischemic and tumor neovasculature are derived by neovasculogenesis, whereby bone marrow (BM)-derived circulating endothelial progenitor cells (EPCs) home to sites of regenerative or malignant growth and contribute to blood vessel formation. Recent data from animal models suggest that a variety of cell types, including unfractionated BM mononuclear cells and those obtained by ex vivo expansion of human peripheral blood or enriched progenitors, can function as EPCs to promote tissue vasculogenesis, regeneration, and repair when introduced in vivo. The promising preclinical results have led to several human clinical trials using BM as a potential source of EPCs in cardiac repair as well as ongoing basic research on using EPCs in tissue engineering or as cell therapy to target tumor growth.

Original languageEnglish (US)
Pages (from-to)421-429
Number of pages9
JournalProgress in Cardiovascular Diseases
Issue number6
StatePublished - May 2007

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Biologic Properties of Endothelial Progenitor Cells and Their Potential for Cell Therapy'. Together they form a unique fingerprint.

Cite this